GRPR and cancer: During recent years, properly tailored BBN-like peptides have been proposed as theranostic anti-cancer agents, capable of delivering diagnostic (gamma/positron emitting) radionuclides or therapeutic payloads (beta− and alpha particle emitters) to GRPR-expressing tumor lesions.